Replies to post #497 on Aethlon Medical Inc (AEMD)

[GWMAN]

2009 Calendar, Coverage, Slides, etc.

==> The Robins Group Coverage (Dec. 3, 2008)

Note: Earnings Estimate for Calendar 2009 is 0.14; based on calendar in coverage being overly optimistic, my personal hope is that AEMD will earn 0.00-0.05 for calendar 2009

http://www.therobinsgroup.biz/files/12_03_08_AEMD_IC.pdf


==> Latest Letter to Shareholders (Feb. 24, 2009)

http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1259383&highlight=


==> Video of RedChip Conference Presentation, accompanying slides and follow-up RedChipTV interview (Mar. 24, 2009)

http://www.redchip.com/visibility/conferencePages/SanFran2009/conferenceMain.asp?page=archive


==> Latest CEO Webcast (Mar. 5, 2009)

http://www.ceocast.com/(1t5vjl331gce04nvkcnow433)/company.aspx?id=1049


==> Current Chart TA

http://www.stockta.com/cgi-bin/analysis.pl?symb=AEMD&num1=13&cobrand=&mode=stock


==> Updated 2009 Calendar

**Note that I will be bolding the milestones that have been acheived as I update this periodically.

March:

1. Results from HIV study (DONE)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1265082&highlight=

2. Results from 30-day HCV study (Semi-DONE)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1269792&highlight=


April:

1. Notification on potential award from Bill and Melinda Gates Foundation (DONE)

Note: AEMD did not get this Round 2 grant, largely because the objective identified in the grant application was acheived by the company in India before the Gates Foundation even made a decision on whether or not to award AEMD a grant. The Gates Foundation encouraged AEMD to refine the application and resubmit it for Round 3.


May/June:

1. Notification on potential 5-year contract award from BARDA/fed gov

2. Release of Annual Report

3. Completion of GMP Manufacturing and Quality Systems to allow commerical export


Other 2009 Milestones (targeted month unknown):

1. Announcment of agreement to treat Dengue Fever in India

Note recent addition to team of Director of Business Development from India, http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1248744&highlight=

2. Establish data-supported HIV strategy for Undetectable Viral Load (DONE)
http://finance.yahoo.com/news/Aethlon-Medical-Discloses-New-prnews-15132368.html?.v=1

3. Close on strategic partnership(s) and negotiate strategic investment

4. Announcment on the planned contract production partner referenced in the investment firm write-up (DONE)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1262531&highlight=

5. Initiation of commerical production for sale of product in India

6. Starting of clinical trials in U.S. involving 10-patient safety study mimicing what has already been conducted in India (Described by CEO as near-term objective at RedChip Conference)

7. Define regulatory and commericalization plan for European Union

8. Complete currently ongoing in-vitro Cytomegalovirus study

9. Announce research plan and progress to concetnrate and subsequently identify new viruses underlying specific diseases and identify biomarkers that can be targetes for drug intervention.

10. Announce research progress to advance adjunct cancer treatment possibilities.